Reply to Olle et al. - Summary - MDSpire

Reply to Olle et al.

  • By

  • Brendan J Kelly

  • Jennie H Kwon

  • Michael H Woodworth

  • November 19, 2024

  • 0 min

Share

Objective:

To clarify the distinction between 'fecal microbiota product' and 'live biotherapeutic product' in microbiome-based therapeutics.

Key Findings:
  • Clear terminology helps clinicians distinguish between treatment modalities.
  • Fecal microbiota products and live biotherapeutic products may enhance treatment for Clostridioides difficile infection and multidrug-resistant infections.
Interpretation:

The distinction in terminology is crucial for effective communication and treatment strategies in microbiome therapies.

Limitations:
Conclusion:

Both fecal microbiota products and live biotherapeutic products are expected to remain valuable for treating infections and advancing scientific understanding.

Original Source(s)

Reply to Olle et al.

  • by Brendan J Kelly, Jennie H Kwon, Michael H Woodworth

  • November 19, 2024

Related Content

Inflammation Tied to Organ Failure Risk

Review outlines mechanisms, prognosis, and supportive care strategies in surgical and trauma ICU populations

Insights from Multi-Omics on Maternal-Fetal Immune Tolerance in Recurrent Pregnancy Loss: Mechanisms, Integration Challenges, and Clinical Implications

Side Effects: Four Studies Worth Passing On

Kissing celiacs, Ozempic genes, Viagra for the brain, and a UTI test that actually works. This week's evidence is weird, useful, and worth your time.